clinical trial · NCT05462587
A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II
Leukocyte Adhesion DeficiencyAVTX-803 (L-Fucose)
brief summary
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
started
Jul 28, 2022
primary completion
Nov 30, 2024
completion
Nov 30, 2024
last updated
Nov 1, 2024
official title
A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol